ERBB2 and cancer: Active targeting involves the functionalization of AuNP surfaces by targeting moieties, which are specific to a wide range of overexpressed surface receptors in the cancer cells, such as EGFR (epidermal growth factor receptor), human epidermal growth factor receptor-2 (HER-2) and CD44 [38,101] and molecules in the TME [102,103].